Market Overview

Cynapsus Therapeutics Developing New Parkinson's Treatment That Won't Require Injection

Share:

Janney's Ken Trbovich initiated a Buy rating on Cynapsus Therapeutics Inc (Nasdaq: CYNA) and set a price target of $24.

The company has successfully developed and marketed Apomorphine (APO) for 20 years to combat Parkinson's disease in Europe and the US. A relatively big drawback for the treatment, despite its success, is the subcutaneous injection that is necessary. Cynapsus is developing a sublingual APO that will eliminate this injection. Trobovich sees a high rate of clinical and commercial success for the new treatment.

The OFF condition, which APO alleviates, is a problem for every patient afflicted with this disease. APO has been successful in battling the disease and has produced numerous positive outcomes for patients over the years, but the treatments subcutaneous injection has limited its use.

"It is rarely used in the U.S. and sales in Europe last year were just $63 million," Trobovich stated.

Cynapsus plans to report Phase 3 trial results for its new sublingual APO in late Q2 or early Q3.

Latest Ratings for CYNA

DateFirmActionFromTo
Jun 2016Initiates Coverage onBuy
Apr 2016Initiates Coverage onOutperform

View More Analyst Ratings for CYNA
View the Latest Analyst Ratings

Posted-In: Janney Ken TrbovichAnalyst Color Health Care Initiation Analyst Ratings General

 

Related Articles (CYNA)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LOWRBC CapitalMaintains129.0
MARRBC CapitalMaintains148.0
CRLSunTrust Robinson HumphreyMaintains162.0
CFRSunTrust Robinson HumphreyMaintains105.0
ZYNEJefferiesAssumes11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Cepheid Margin Expansion Unlikely To Morgan Stanley, Stays On Sidelines

BMO Calls Market Response To Synchrony Guidance An Overreaction